May 17, 2024PLoS ONEOpen Access

In-silico formulation of a next-generation polyvalent vaccine against multiple strains of monkeypox virus and other related poxviruses

View Full Paper

Ask AI

Bookmark

Engineered polyvalent vaccine construct 1 exhibits high antigenicity and non-toxicity, and molecular dynamic simulation indicates greater complex stability with TLR8 than TLR3.
Reverse vaccinology mapping of virulent MPXVgp165 and core P4a proteins yielded conserved T cell epitopes and B cell epitopes linked with human beta-defensins adjuvants.
Computational stability of the TLR8 complex supports cross-protection against poxviruses, but in vitro and in vivo experimental validation is required to confirm immunogenicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Reverse vaccinology study demonstrates stable multi-epitope vaccine candidates against monkeypox virus, suggesting cross-protective efficacy across poxviruses.

Cite This Study

Moin et al. (2024) studied this question.

synapsesocial.com/papers/68e69852b6db64358761e66f https://doi.org/10.1371/journal.pone.0300778

View Full Paper

Ask AI

Bookmark

Implication

Reverse vaccinology study demonstrates stable multi-epitope vaccine candidates against monkeypox virus, suggesting cross-protective efficacy across poxviruses.

In-silico formulation of a next-generation polyvalent vaccine against multiple strains of monkeypox virus and other related poxviruses

Key Points

Discussion

Implication

Cite This Study

In-silico formulation of a next-generation polyvalent vaccine against multiple strains of monkeypox virus and other related poxviruses

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider